COVID-19 in Long-Term Care Facilities: An Update

Joseph G. Ouslander, MD

Professor of Geriatric Medicine
Senior Advisor to the Dean for Geriatrics
Charles E. Schmidt College of Medicine
Professor (Courtesy), Christine E. Lynn
College of Nursing
Florida Atlantic University

Executive Editor, Journal of the American Geriatrics Society
- Public University with over 25,000 students
- Fully accredited medical school and internal medicine, emergency medicine, surgery, and neurology, and psychiatry residency programs
Disclosures

- Dr. Ouslander is a full-time employee of Florida Atlantic University (FAU) and has received support through FAU for research on INTERACT from the National Institutes of Health, the Centers for Medicare & Medicaid Services, The Commonwealth Fund, the Retirement Research Foundation, PointClickCare, Medline Industries, and Think Research.

- Dr. Ouslander and his wife receive royalties from FAU and Pathway Health for training on and licensing of the INTERACT program.

- Work on funded INTERACT projects is subject to the terms of Conflict of Interest Management plans developed and approved by the FAU Financial Conflict of Interest Committee.
LTCF is a broad term that can include many types of facilities. This presentation focuses on LTCFs that are generally referred to as “skilled nursing facilities”, “nursing facilities”, and “nursing homes”.

People who reside in these facilities are there for different reasons and differ clinically:
- “Patients” who are there for post-acute care after discharge from the hospital
- “Residents” who require long-term care

LTCF patients and residents are generally at high risk for complications of and mortality from COVID-19:
- Multiple chronic conditions
- Advance age
LTCF patients and residents frequently do not have typical symptoms and signs of COVID-19
- No symptoms – up to 50% or higher
- Atypical symptoms – e.g. low grade temperature elevation; altered mental or functional status; GI symptoms

LTCF staff may have no symptoms, no fever, and pass multiple screening tests, and still be infected
- They also may be working multiple jobs at different facilities and be at high risk
- They can therefore infect other staff and residents without knowing it

The only way to prevent infection and further spread of infection is behavior – intensive infection control procedures
COVID-19 in Long-Term Care Facilities: An Update

Key Points: Use of PPE and Isolation

- All staff must use some form of mask at all times, maintain “social distancing” and wash or sanitize hands frequently
  - CDC guidelines should be followed
- As much Personal Protective Equipment (PPE) as is available should be used with any patient/resident suspected of having COVID or has an acute change in condition without an obvious cause
  - PPE should also be used during high risk or close contact procedures, including nebulizer treatments
- Because symptoms and signs may be atypical, there should be a low threshold for placing patients/residents on precautions, isolation or in quarantine areas
  - Check vital signs and for other changes in condition frequently (e.g. every shift)
- Isolation can be hard for the patients/residents
  - Use video calls or other strategies to connect with families whenever possible
Shortages of PPE persist and will recur in many areas
  - CDC guidelines should be followed to preserve PPE

Availability of testing is variable and is still hard to get in a timely way except during suspected outbreaks
  - This further highlights the necessity of intensive infection control procedures
Clinicians should do as many visits as possible over the phone or by telemedicine if available
- CMS has changed payment rules and requirements for in-person visits

Use available tools to determine what needs immediate vs. non-immediate clinician intervention and what can be evaluated by phone or by telemedicine vs. in-person visits
- AMDA Practice Guideline on Notification
- INTERACT Change in Condition Cards and Care Paths

Available free for clinical and educational use at www.pathway-interact.com

<table>
<thead>
<tr>
<th>Signs and Symptoms</th>
<th>Immediate</th>
<th>Non-Immediate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal Pain</td>
<td>Abrupt onset severe pain or distention, C/O with fever, vomiting</td>
<td>Mild diffuse or localized pain, unrelieved by antacids or laxatives</td>
</tr>
<tr>
<td>Abdominal Distention</td>
<td>Rapid onset, C/O presence of marked tenderness, fever, vomiting, GI bleeding</td>
<td>Progressive or persistent distention not associated with symptoms</td>
</tr>
<tr>
<td>Abdominal Tenderness</td>
<td>Associated with fever, continuous GI bleeding, or other acute symptoms</td>
<td>Persistent discomfort not associated with other acute symptoms</td>
</tr>
<tr>
<td>Abdomen</td>
<td>Accompanied by significant pain or bleeding</td>
<td>If bleeding continues of if associated with evidence of local infection</td>
</tr>
<tr>
<td>Agitation</td>
<td>Abrupt onset of significant change from usual, C/O associated with fever or new onset abdominal or neurological signs</td>
<td>Continued progression or persistence of symptoms</td>
</tr>
<tr>
<td>Altered Mental Status</td>
<td>Abrupt significant change in cognitive function from usual with or without altered level of consciousness</td>
<td>Persistent change from usual cognitive function with no other criteria met for immediate notification</td>
</tr>
<tr>
<td>Appetite, Diminished</td>
<td>No oral intake 2 consecutive meals</td>
<td>Significant decline in food and fluid intake in resident with marginal hydration and nutritional status</td>
</tr>
<tr>
<td>Anemia</td>
<td>Astute episode with wheezing, dyspnea, or respiratory distress</td>
<td>Self-limited episode that was more intense or less responsive to treatment than the usual</td>
</tr>
</tbody>
</table>
COVID-19 in Long-Term Care Facilities: An Update

Key Points: Medication Management and Deprescribing

- Reducing number of medications, number of doses, and monitoring parameters will:
  - Reduce risk of viral transmission
  - Decrease staff burden and time

- Strategies**
  - Discontinuation or reduction of unnecessary or minimally beneficial medications and monitoring
  - Changes to medication formulations and dosing regimens
  - Appropriate alignment of medication administration times

- Examples of medications to discontinue:
  - Vitamins, herbals, docusate, appetite stimulants, cranberry tablets, chronic probiotics**
  - Ineffective, potentially harmful medications in residents with life-limiting illness
    - Statins, anticoagulants, cholinesterase inhibitors
    - Overtreatment of hypertension; no benefit and risk of falls, syncope
    - Overtreatment of diabetes – especially sliding scales; high risk for hypoglycemia and too much unnecessary nursing staff monitoring time for BP checks and finger stick glucose levels

**Implementation Guide to Optimizing Medication Management in Post-Acute and Long-Term Care during the COVID-19 Pandemic
Nicole Brandt, PharmD, Michael Steinman, MD et al, in preparation
The mortality rate from COVID-19 will be high in the LTCF population, and clinical deterioration can occur rapidly.

Clinicians and LTCF staff should therefore conduct advance care planning discussions and update advance directives in light of the Coronavirus pandemic.

- The pandemic provides an opportunity to hold discussions that may have been difficult previously and to create COVID-specific directives.

Advance Care Planning requires a team approach.

- Ultimately, this requires a trusting relationship between the patient/resident and the team.
- Engage local palliative care and hospice clinicians and teams where available.
Many educational and documentation tools are available
- Using evidence on prognosis (e.g. www.ePrognosis.com) and simple language descriptions of risks and benefits, such as those available in the INTERACT program are helpful
- Being clear about the limited meaning of “DNR” is also helpful
- COVID-19 specific tools are available
  - https://respectingchoices.org/covid-19-resources/
  - https://www.vitaltalk.org/guides/covid-19-communication-skills/
  - https://www.capc.org/toolkits/covid-19-response-resources/

Documenting and communicating discussions and decisions is critical so that hospital transfers and other interventions are either implemented or withheld based on the patient/resident and family preferences

Be prepared for patients/residents dying in the facility
- Check emergency kits and stock with medications for comfort
  - Liquid morphine – injectable and oral/sublingual for respiratory distress
  - Lorazepam - injectable and oral/sublingual for anxiety/agitation
  - Atropine – liquid for secretions
Federal, state, county, and local regulations and guidance vary relative to inter-facility transfers

LTCFs should limit transfers to Emergency Departments and hospitalizations to clinical conditions that require specialized testing and/or and acute or ICU level of care

AMDA Clinical Practice Guidelines, the INTERACT program, and other similar tools should be used to help manage patients/residents in the facility whenever safe and feasible

Patients/residents should have clearly documented advance directives if they are transferred to the extent that the patient/resident is capable of making their own decisions or there is a health care proxy available

Complete critical clinical information should accompany patients/residents using state mandated forms, the INTERACT transfer form, or a similar form that includes the information listed on the INTERACT transfer data list
Hospital patients should be discharged home whenever enough support is available to manage them safely outside of a post-acute facility.

Unless otherwise overridden by state, county or local regulations:

- COVID-19 positive patients should no longer have symptoms and two negative tests 24 hours apart before being transferred from hospital to LTCF or meet CDC criteria:
  - No fever or respiratory symptoms for 72 hours and 7 or more days since onset of symptoms
  - Any patient being transferred from hospital to LTCF for any condition without a COVID-19 test result should be presumed to be infected, and isolated for at least 7 days
  - Based on risk of acquiring the virus in the hospital and nonspecificity of symptoms

Hospitals should provide critical clinical information to post-acute settings using state information should accompany patients/residents using state mandated forms, the INTERACT transfer form, or a similar form that includes the information listed on the INTERACT transfer data list:

- This is especially important in settings where clinicians and other health professionals cannot access the hospital electronic medical record.
As rapid testing and self-testing becomes more available, it will be easier to test all patients/residents and staff, and quarantine them as appropriate.

False negative tests do occur.

Testing serum will help identify who has been infected:
- This will help with quarantine and staffing decisions
- Convalescent serum/plasma may be a therapeutic option, however:
  - Not all people develop high antibody levels
  - Duration of immunity is unknown – may be a few months
COVID-19 in Long-Term Care Facilities: An Update

Next Steps and Planning for the Future: Testing and Treatment

- Currently **there is no evidence-based drug treatment for COVID-19**
  - **Hydroxychloroquine**, with or without azithromycin may be helpful in treating the intense inflammatory response, but:
    - The data are basically anecdotal; results of controlled trials are pending but unlikely to include LTCF patients/residents
    - The drug has numerous potentially severe adverse effects, including sudden death in people with prolonged QT interval, and electrolyte and liver function abnormalities
    - Several potentially serious drug interactions
    - If it is used:
      - Consent should be documented
      - EKG performed before treatment
    - **Guidance on dosing** (intended for hospitals) was removed from the CDC website
  - Other drugs, including antiviral agents and immune modulators are under investigation as is convalescent serum/plasma
  - Vaccines are under development and should help prevent future waves of COVID disease
COVID-19 in Long-Term Care Facilities: An Update

Next Steps and Planning for the Future: Alternative Sites of Care

- Many areas are developing plans for alternative sites of care for patients who are suspected of or are recovering from COVID-19
  - Converting entire LTCFs
  - Using unoccupied wings of existing facilities
  - Critical access hospitals with swing beds
  - Temporary facilities

- Planning is complicated and requires cooperation between LTCFs, hospitals, county and state authorities
  - Regulatory, financial and liability issues need to be addressed

- Staffing and adequate PPE will be challenging
COVID-19 in Long-Term Care Facilities: An Update

Next Steps and Planning for the Future: A Framework for Preparedness

### Framework for Post-Acute Care Preparedness in a COVID-19 World: Key Strategies

<table>
<thead>
<tr>
<th>Stage One: Survive the Surge</th>
<th>Stage Two: Regroup and Prepare</th>
<th>Stage Three: Restructure to Recovery</th>
<th>Stage Four: Redesign to Reality</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Outplace non-COVID patients in non-acute hospitals</td>
<td>1. Protect vulnerable populations from COVID infection</td>
<td>1. Tap post-acute providers to participate in front lines of distribution and administration of prophylaxis, vaccinations</td>
<td>1. Create local hospital/post-acute/public health advisory bodies</td>
</tr>
<tr>
<td>2. Assess capacity of SNFs and HHAs and other sources of care to enable hospital discharges for non-COVID patients</td>
<td>2. Prepare treat-in-place protocols for non-COVID admissions</td>
<td>2. Continue and deepen strategies to deliver non-COVID related medical care at home and in residential care communities</td>
<td>2. Identify opportunities to optimize post-acute care at market level for system performance moving forward</td>
</tr>
<tr>
<td>3. Direct regional post-acute care providers to identify separate, specialized capacity for COVID-positive discharges</td>
<td>3. Create and formalize post-acute care COVID designations and create transfer protocols for various designations</td>
<td>3. Prepare strategic plan for transition</td>
<td>3. Create, revise, and revisit pandemic response plan to include optimal use of all delivery system resources, supplies/equipment, and staff necessary to meet demand</td>
</tr>
</tbody>
</table>

COVID-19 in Long-Term Care Facilities: An Update

Selected References

- Websites
  - CDC, CMS
  - American Geriatrics Society
  - AMDA/The Society for Post-Acute and Long-Term Care Medicine
  - Center to Advance Palliative Care, Vital Talk, Respecting Choices

- Coronavirus-19 in Geriatrics and Long-Term Care: An Update
  Available at: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgs.16464

- Coronavirus Disease 2019 in Geriatrics and Long-term Care: The ABCDs of COVID-19
  Available at: https://onlinelibrary.wiley.com/doi/10.1111/jgs.16445

- COVID-19 in Older Adults: Transfers Between Nursing Homes and Hospitals

- Lessons Learned from the COVID-19 Outbreak at Canterbury Rehab, 3/29/2020
  Available at: https://cmda.us/resources/COVID%20Lessons%20from%20Battlefield%20Handout.pdf

- Post-Acute Care Preparedness in a COVID-19 World
  Available at: https://atiadvisory.com/work/post-acute-care-preparedness-in-a-covid-19-world/
Questions?  Comments?  Suggestions?

Joseph G. Ouslander, MD

jousland@health.fau.edu